Targeting PD-1 Pathway; A new hope for Gastrointestinal Cancers.

CONCLUSION: Both pembrolizumab and nivolumab showed promising efficacy with acceptable safety data in GI cancers especially in refractory MSI positive metastatic colorectal cancer in the era of published trials.
PMID: 28055269 [PubMed - as supplied by publisher]

Source: Current Medical Research and Opinion - January 7, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research